The Mobi-C is a cobalt chromium alloy and polyethylene prosthesis. It is designed to be bone-sparing and serve as an alternative to fusion.
LDR completed the rigorous process of obtaining FDA pre-market approval, including conducting a 24-month clinical study. Results showed the Mobi-C had a success rate of 69.7 percent compared with ACDF’s rate of 37.4 percent.
Patients in the study were also able to return to work at 45.9 days with the Mobi-C compared with 66.8 days for ACDF.
More Articles on Devices:
Interventional Spine Receives Minimally Invasive Fusion Device Patent
IlluminOss Medical Names Dwayne Montgomery as Senior Vice President of Sales
InVivo Therapeutics Appoints Interim CEO, CFO to Replace Francis Reynolds
